Aptiv Solutions Launches ADDPLAN DF 3.0

Article

Applied Clinical Trials

ICON announced that Aptiv Solutions, an ICON company for the design and implementation of adaptive trials, has released ADDPLAN DF 3.0

ICON announced that Aptiv Solutions, an ICON company for the design and implementation of adaptive trials, has released ADDPLAN DF 3.0, which incorporates complex statistical methodologies to prevent under and over-estimation of a therapeutic’s maximum target dose (MTD) during Phase I dose escalation trials. Accurate estimation of MTD can minimize safety and efficacy issues leading to late phase clinical trial failures.

Read the full release here.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Related Content
© 2024 MJH Life Sciences

All rights reserved.